New test improves diagnosis of chronic lymphocytic leukemia

June 30, 2015 News Quality by Design - Business & Communications

Chronic Lymphocytic Leukemia or CLL is the most common form of leukemia in adults and has a highly variable outcome. Patients experience prolonged periods of disease stabilization – the cancer is neither decreasing nor increasing in extent or severity. But at any given time, CLL can progress very fast, requiring appropriate treatment adjustments to keep progression at bay. Genetic analysis is an important tool in the differential diagnosis and distinguishes between ‘stable disease’ and ‘progression’.

Multiplicom’s new test helps to steer the treatment options to stabilize the disease. It detects single nucleotide variants as well as copy number alterations. The identification of mutations in TP53, BIRC3, NOTCH1 and SF3B1 enables a more refined prognostic stratification, while the detection of TP53 mutations has therapeutic value as it guides treatment with alemtuzumab and/or steroids, which may be followed by allogeneic stem cell transplantation.

Avatar photo
Quality by Design - Business & Communications

Quality by Design (QbD) - Business & Communications is a team of expert strategists, scientists, communicators, and creatives. Whether you're a part of an innovative startup or an established player, our unique approach will ensure that your company has the best chance of being seen and understood by your target audience: prospects, clients, investors, partners, and more. We don’t just consult; we also help you implement. We share articles on BioVox providing insight into new and established players in the Benelux Life Science ecosystem, from innovations and research breakthroughs through to finance and industry trends.

All posts

Subscribe to the BioVox newsletter